B+
Bull case
25%
Probability
Target price
$11.50
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
EOLS
EvolusBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$9.60
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-08-25 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-25
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+75.9
Score
AI commentary
Primary-source tone is constructive after Q2, but the evidence set is low coverage and lacks reliable social, options, short-interest, employee, analyst-revision, and post-print reaction data. The result is a cautious monitoring thesis rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-08-25
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-31catalystQ2 execution and raised FY2026 outlookHigh impact
Q2 revenue rose 21% to $84.1 million, adjusted EBITDA was positive at $4.7 million for the third consecutive quarter, and management raised 2026 revenue and adjusted gross-margin guidance. Continued execution could support a cautious rerating [#SEC-8K-2026-08-05].
2026-12-31eventPotential Evolysse Sculpt U.S. approvalHigh impact
Management continued to anticipate U.S. approval of Evolysse Sculpt later in 2026. Approval would broaden the commercial portfolio, while delay would pressure the growth thesis [#SEC-8K-2026-05-04].
2028-12-31catalystPortfolio and international expansionHigh impact
Evolus added Profhilo through an IBSA partnership, launched Estyme in Europe, and expanded rights into Canada, Australia, and New Zealand. Profhilo commercialization is anticipated around 2030, while the expanded international rights target commercialization in 2028 [#SEC-8K-2026-08-05].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-25 • Updated nightlySource: Internal modelMethodology